Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury · TBI
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 2
2 studies reported at therapy level; 2 evidence entries itemised.
MouseSpinal cord injuryUnspecifiedC57BL/6MaleAcute and chronic phases after injury examined
Model: Spinal cord injury with parallel studies in cultured spinal cord neurons
Lithium inhibited GSK3 beta through AKT phosphorylation acutely and through Na,K-ATPase alpha1 and SGK1 chronically, raising nuclear beta-catenin and supporting neuronal survival.
Extraction: extract · Supplied extraction confidence: 0.5. Machine-extracted fields require source verification.
MouseTBIUnspecifiedC57BL/6maleIntraperitoneal1.5 mEq/kgFirst dose 15 min after traumatic brain injury
Model: Controlled traumatic brain injury in mice
Lithium attenuated the injury induced increases in beta amyloid load, amyloid precursor protein accumulation and BACE1 overexpression at 3 days, reduced thalamic Tau phosphorylation, and significantly improved spatial learning and memory in the Y-maze and Morris water maze alongside greater hippoca…
Extraction: extract · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
